Lipids & metabolic liver disease
Comparative efficacy and safety of pharmacologic therapies for metabolic dysfunction‐associated steatotic liver disease over 24 weeks in reducing liver steatosis and fibrosis: A network meta‐analysis
Authors' conclusion
This comprehensive network meta-analysis demonstrates the varying efficacy of pharmacologic interventions for MASLD, with resmetirom and pegozafermin emerging as particularly promising treatments for steatosis and fibrosis, respectively. While most treatments exhibited favourable safety profiles, careful monitoring is warranted, particularly with efruxifermin due to its slightly elevated adverse event profile. These findings provide valuable evidence to guide clinical decision-making in MASLD management, though longer-term studies are needed to confirm the durability of these therapeutic effects and further establish safety profiles.
Study context
- Population
- Randomized controlled trials (RCTs) of pharmacologic treatments for metabolic-associated steatotic liver disease (MASLD) over 24 weeks23 RCTs
- Comparison
- Pharmacologic therapies for MASLD vs placebo
- Outcome
- Change in liver steatosis (MRI proton density fat fraction) and fibrosis (MR elastography-derived liver stiffness)
- Follow-up
- 24 weeks
Methodological detailsBayesian framework
- Bayesian framework
Pooled result
As reported in the abstract
- Pegozafermin · fibrosis; greatest effect
- −4.85 (95% CI −5.50 to −4.19)
Safety
| Outcome | Estimate |
|---|---|
| Adverse eventsEfruxifermin vs Placebo · slightly higher adverse events with efruxifermin | 0.32 (95% CI 0.06–0.70) |
Adverse events
- Most treatments showed acceptable safety profiles
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →